1. Academic Validation
  2. In vitro and in vivo antibacterial activities of the fluoroquinolone WIN 49375 (amifloxacin)

In vitro and in vivo antibacterial activities of the fluoroquinolone WIN 49375 (amifloxacin)

  • Antimicrob Agents Chemother. 1985 Jan;27(1):4-10. doi: 10.1128/AAC.27.1.4.
J B Cornett R B Wagner R A Dobson M P Wentland D M Bailey
Abstract

WIN 49375 (amifloxacin) is a synthetic Antibacterial agent of the Quinolone class. It is similar in chemical structure to pefloxacin but differs by containing a methylamino, rather than an ethyl, substituent at the 1-N position. The activity of WIN 49375 in vitro was comparable to those of norfloxacin and pefloxacin against Enterobacteriaceae and generally greater than those of tobramycin and cefotaxime. WIN 49375 was more active in vitro than carbenicillin and mezlocillin against Pseudomonas aeruginosa isolates and showed moderate activity against Staphylococcus aureus, with MICs of less than or equal to 2 micrograms/ml. The in vitro activity of WIN 49375 was not markedly affected by the presence of human serum, the size of the Bacterial inoculum, or changes in pH between 6 and 8. Against systemic, gram-negative Bacterial infections in mice, WIN 49375 was generally less active than cefotaxime but more active than gentamicin. WIN 49548, the major piperazinyl-N-desmethyl metabolite of WIN 49375, was aa effective as the parent drug against experimental infections in mice when given parenterally. When administered orally, however, this metabolite was less potent than WIN 49375. WIN 49375 was highly active by the oral route, with 50% effective doses within two- to threefold of those obtained with parenteral medication.

Figures
Products